New technologies and collaborative care are improving the quality of life of patients with glaucoma
Glaucoma is one of the leading causes of irreversible blindness in the world, estimated to affect 66 million people worldwide and some 300 000 Australians.1,2 The majority of glaucoma patients present with progressive asymptomatic visual loss, with over 50% remaining undiagnosed.3 Annual costs of glaucoma to the health system in Australia are estimated to increase from $355 million in 2005 to $784 million by 2025.2 Management of this disease requires early detection, encouraging treatment adherence, improving patients’ quality of life and advancing medical research. To achieve this, strong collaboration is required between ophthalmologists, optometrists, orthoptists, pharmacists, general practitioners, patient advocacy groups like Glaucoma Australia and the Royal Australian and New Zealand College of Ophthalmologists, and funding bodies.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262–267.
- 2. Dirani M, Crowston JG, Taylor PS, et al. Economic impact of primary open‐angle glaucoma in Australia. Clin Exp Ophthalmol 2011; 39(7): 623–632. Epub 2011/06/03.
- 3. Keel S, Xie J, Foreman J, et al. Prevalence of glaucoma in the Australian National Eye Health Survey. Br J Ophthalmol 2018; https://doi.org/10.1136/bjophthalmol-2017-311786 [Epub ahead of print].
- 4. Shiga Y, Akiyama M, Nishiguchi KM, et al. Genome‐wide association study identifies seven novel susceptibility loci for primary open‐angle glaucoma. Hum Mol Gen 2018; 27: 1486–1496.
- 5. National Health and Medical Research Council. NHMRC guidelines for the screening, prognosis, diagnosis, management and prevention of glaucoma. Canberra: NHMRC, 2010.
- 6. Sood V, Ramanathan US. Self‐monitoring of intraocular pressure outside of normal office hours using rebound tonometry: initial clinical experience in patients with normal tension glaucoma. J Glaucoma 2016; 25: 807–811.
- 7. Anderson AJ, Bedggood PA, George Kong YX, et al. Can home monitoring allow earlier detection of rapid visual field progression in glaucoma? Ophthalmology 2017; 124: 1735–1742.
- 8. Li Z, He Y, Keel S, et al. Efficacy of a deep learning system for detecting glaucomatous optic neuropathy based on color fundus photographs. Ophthalmology 2018; 125: 1199–1206.
- 9. Katz LJ, Steinmann WC, Kabir A, et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J Glaucoma 2012; 21: 460–468.
- 10. Gazzard G, Konstantakopoulou E, Garway‐Heath D, et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology. Br J Ophthalmol 2018; 102: 593–598.
- 11. Lavia C, Dallorto L, Maule M, et al. Minimally‐invasive glaucoma surgeries (MIGS) for open angle glaucoma: a systematic review and meta‐analysis. PloS One 2017; 12: e0183142.
- 12. Skalicky SE, D'Mellow G, House P, et al. Glaucoma Australia educational impact study: a randomized short‐term clinical trial evaluating the association between glaucoma education and patient knowledge, anxiety and treatment satisfaction. Clin Exp Ophthalmol 2018; 46: 222–231.
- 13. Kong YX, van Bergen N, Bui BV, et al. Impact of aging and diet restriction on retinal function during and after acute intraocular pressure injury. Neurobiol Aging 2012; 33(1126): e1115–1125.
- 14. Williams PA, Harder JM, Foxworth NE, et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science 2017; 355: 756–760.
- 15. Calkins DJ, Pekny M, Cooper ML, et al. The challenge of regenerative therapies for the optic nerve in glaucoma. Exp Eye Res 2017; 157: 28–33.
Yu Xiang George Kong is supported by an Ophthalmic Research Institute of Australia New Investigator Grant.
Yu Xiang George Kong is Director of GLANCE Optical Pty Ltd.